Posted inCardiology Diabetes & Endocrinology news
GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events
This emulation study applies SELECT trial data to over 600,000 individuals, suggesting that GLP-1RAs could significantly reduce 10-year cardiovascular risk in high-risk obese populations without existing disease, offering a potential 22% relative risk reduction.



















